X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (204) 204
index medicus (145) 145
gastroenterology & hepatology (141) 141
female (122) 122
male (122) 122
middle aged (108) 108
hepatitis c (106) 106
hepatitis c virus (86) 86
adult (78) 78
antiviral agents - therapeutic use (77) 77
hepacivirus - genetics (69) 69
gastroenterology and hepatology (68) 68
aged (65) 65
liver (65) 65
liver transplantation (65) 65
cirrhosis (59) 59
hepatitis c, chronic - drug therapy (57) 57
hepatitis (55) 55
infection (52) 52
recurrence (51) 51
transplantation (50) 50
interferon (47) 47
ribavirin (47) 47
treatment outcome (45) 45
genotype (43) 43
drug therapy, combination (39) 39
health aspects (39) 39
antiviral agents (36) 36
ribavirin - therapeutic use (36) 36
antiviral therapy (35) 35
viral load (34) 34
hepatitis c - virology (32) 32
hcv (31) 31
liver cirrhosis (31) 31
analysis (30) 30
hepatitis c - drug therapy (30) 30
risk factors (30) 30
hepatitis c, chronic - virology (29) 29
antiviral agents - adverse effects (28) 28
care and treatment (28) 28
liver diseases (27) 27
fibrosis (26) 26
interferon-alpha - therapeutic use (26) 26
biopsy (25) 25
hepatitis c, chronic - complications (25) 25
virology (25) 25
virus-infection (25) 25
patients (24) 24
therapy (24) 24
sofosbuvir (23) 23
biological response modifiers (22) 22
infections (22) 22
liver cirrhosis - virology (22) 22
sustained virological response (22) 22
hepacivirus - drug effects (21) 21
hepatitis c - complications (21) 21
viruses (21) 21
hepatology (20) 20
time factors (20) 20
abridged index medicus (19) 19
follow-up studies (19) 19
genotypes (19) 19
liver - pathology (19) 19
disease (18) 18
medical research (18) 18
prevalence (18) 18
retrospective studies (18) 18
rna (18) 18
spain (18) 18
virus diseases (18) 18
hepatitis c - diagnosis (17) 17
hepatitis-c virus (17) 17
hepatocellular-carcinoma (17) 17
prospective studies (17) 17
telaprevir (17) 17
clinical trials (16) 16
hcv infection (16) 16
medicine, experimental (16) 16
microbiology (16) 16
rna, viral - blood (16) 16
surgery (16) 16
air pollution (15) 15
antiviral agents - administration & dosage (15) 15
boceprevir (15) 15
drug therapy (15) 15
efficacy (15) 15
hepacivirus - immunology (15) 15
hepacivirus - isolation & purification (15) 15
liver cirrhosis - diagnosis (15) 15
liver transplantation - adverse effects (15) 15
polyethylene glycols - therapeutic use (15) 15
recipients (15) 15
rna, viral - genetics (15) 15
aged, 80 and over (14) 14
child (14) 14
genotype & phenotype (14) 14
hepacivirus - classification (14) 14
hepacivirus - physiology (14) 14
immunology (14) 14
infectious diseases (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2015, Volume 112, Issue 26, pp. 7937 - 7942
Journal Article
Environmental Health Perspectives, ISSN 0091-6765, 04/2016, Volume 124, Issue 4, pp. 529 - 535
Journal Article
PLoS Medicine, ISSN 1549-1277, 03/2015, Volume 12, Issue 3, pp. e1001792 - e1001792
Journal Article
Hepatology, ISSN 0270-9139, 06/2017, Volume 65, Issue 6, pp. 2137 - 2138
Journal Article
Environmental Health Perspectives, ISSN 0091-6765, 2015, Volume 122, Issue 12, pp. 1351 - 1358
Journal Article
Journal of Hepatology, ISSN 0168-8278, 08/2018, Volume 69, Issue 2, p. 544
Treatments of different types of hepatitis C are presented. 
Hepatitis | Medical treatment | Hepatitis C
Journal Article
HEPATOLOGY, ISSN 0270-9139, 06/2017, Volume 65, Issue 6, pp. 2137 - 2138
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 6, pp. 685 - 697
Journal Article
The Lancet Infectious Diseases, ISSN 1473-3099, 12/2017, Volume 17, Issue 12, pp. 1240 - 1240
Exposure and response analyses indicate that decreases in the exposure of glecaprevir (as observed in patients using high doses of proton-pump inhibitors) had... 
Protons | Benzimidazoles | Proton Pump Inhibitors | Sulfonamides | Humans | Quinoxalines | Hepatitis C | Studies | Hepatitis | Technical communication
Journal Article
Gastroenterology, ISSN 0016-5085, 11/2017, Volume 153, Issue 5, pp. 1273 - 1283.e1
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article